Sanara MedTech Inc. reported a significant increase in financial performance for the third quarter of 2025, with net revenue reaching $26.3 million, a 22% increase from $21.7 million in the same period last year. For the nine months ending September 30, 2025, the company generated $75.6 million in revenue, up 25% from $60.4 million in the prior year. The growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical and BIASURGE, as well as certain bone fusion products, attributed to enhanced market penetration and geographic expansion.
Despite the revenue growth, Sanara MedTech reported a net loss of $30.4 million for the third quarter, compared to a loss of $2.9 million in the same period last year. The substantial loss was largely due to a $26.5 million asset impairment charge related to the discontinued Tissue Health Plus (THP) segment, which the company decided to wind down in mid-September 2025 after unsuccessful attempts to find investors. The decision to discontinue THP was influenced by persistent losses and a lack of interest from potential buyers.
Operationally, Sanara MedTech's total assets decreased to $71.1 million as of September 30, 2025, down from $88.1 million at the end of 2024. The company’s liabilities also increased significantly, totaling $64.9 million, compared to $49.2 million at the end of the previous year. The increase in liabilities was primarily due to a rise in long-term debt, which reached $45.1 million, up from $30.7 million at the end of 2024. The company’s cash position slightly decreased to $14.9 million from $15.9 million at the end of 2024.
In terms of strategic developments, Sanara MedTech completed the acquisition of CarePICS in April 2025 for $2 million, which included the assumption of $1.65 million in existing debt. However, following the decision to discontinue the THP segment, the technology developed by CarePICS was deemed to hold no value outside of that segment, leading to a full impairment of its carrying value. The company also made significant investments in Biomimetic Innovations Limited, increasing its ownership stake to approximately 12.5% by October 2025.
Looking ahead, Sanara MedTech anticipates that its cash on hand, combined with expected cash flows from operations and available borrowing under its CRG Term Loan, will be sufficient to fund its operations and growth initiatives for at least the next 12 months. The company has $12.25 million available for future borrowing under the CRG Term Loan, which it plans to utilize for potential acquisitions and further development of its product pipeline.
About Sanara MedTech Inc.
Sanara MedTech Inc. develops and markets innovative medical technologies for surgical, wound, and skincare applications. Its core segments include Sanara Surgical, offering products like collagen and bone grafts, and Tissue Health Plus, providing value-based wound care services. The company focuses on improving clinical outcomes, reducing healthcare costs, and expanding its product pipeline through partnerships, proprietary innovations, and comprehensive care solutions across the U.S. healthcare continuum.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.